Oncology – Page 31

$Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial$

Enhancing Quality of Life in KRASG12C-Mutated Chemorefractory Metastatic Colorectal Cancer: Insights from the CodeBreaK 300 Phase 3 Trial

By MedXY 09/21/2025

The phase 3 CodeBreaK 300 trial shows sotorasib plus panitumumab improves health-related quality of life and clinical outcomes in KRASG12C-mutated metastatic colorectal cancer compared to standard care.

Clinical Updates Oncology Specialties Urology

Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy

By MedXY 09/21/2025

The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant prostate cancer with manageable toxicity.

$Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial$

Clinical Updates news Oncology Specialties

Lenvatinib Plus Pembrolizumab Shows Promise for Platinum-Refractory Advanced B3 Thymoma and Thymic Carcinoma: Insights from the PECATI Phase 2 Trial

By MedXY 09/21/2025

The PECATI phase 2 trial demonstrates that lenvatinib combined with pembrolizumab offers encouraging antitumour activity and a manageable safety profile in platinum-refractory metastatic B3 thymoma and thymic carcinoma, a population with limited treatment options.

Clinical Updates news Oncology Radiology Specialties

De-escalated Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Cancer: Balancing Efficacy with Reduced Toxicity

By MedXY 09/21/2025

This phase 3 trial shows that de-escalated adjuvant radiotherapy reduces chronic grade 3+ toxicities compared to standard chemoradiotherapy in HPV-associated oropharyngeal cancer, potentially improving patient quality of life without compromising treatment.

Clinical Updates news Oncology Radiology

Expanding the Role of Stereotactic Radiosurgery in Small Cell Lung Cancer with Brain Metastases: Insights from a Prospective Multicenter Phase II Trial

By MedXY 09/21/2025

A prospective phase II trial shows stereotactic radiosurgery offers a low neurologic death rate in SCLC patients with 1-10 brain metastases, challenging the traditional favoring of whole-brain radiation therapy.

news Oncology Specialties

Dual Immune Checkpoint Blockade Fails to Improve Outcomes in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007 Phase II Study Results

By MedXY 09/21/2025

The NRG Oncology BN007 trial found that combining ipilimumab with nivolumab did not improve progression-free survival compared to temozolomide in patients with newly diagnosed MGMT-unmethylated glioblastoma, leading to early closure of the study before phase III.

news Oncology Specialties

Obrixtamig (BI 764532): A Promising DLL3/CD3 T-Cell Engager in Heavily Pretreated DLL3-Positive Neuroendocrine Cancers

By MedXY 09/21/2025

Phase I trial of obrixtamig, a DLL3/CD3 T-cell engager, shows tolerability and encouraging efficacy in heavily pretreated patients with DLL3-positive SCLC and neuroendocrine carcinomas, supporting further development.

Clinical Updates General Surgery news Oncology Specialties

Innovative Combination of Cryoablation and Intratumoral Immunotherapy Extends Survival in Advanced Metastatic Cancer

By MedXY 09/21/2025

A phase II trial demonstrates that multiplex intratumoral immunotherapy combining cryoablation with low-dose immune checkpoint inhibitors significantly prolongs median overall survival to 20.9 months in treatment-refractory metastatic solid tumors.

Clinical Updates news Oncology Pathology & Lab Medicine Specialties

Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma

By MedXY 09/20/2025

Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.

Clinical Updates Oncology

Phase III NuTide:121 Trial Shows NUC-1031/Cisplatin Fails to Improve Survival Over Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

By MedXY 09/20/2025

The NuTide:121 phase III trial compared NUC-1031/cisplatin to gemcitabine/cisplatin in treatment-naïve advanced biliary tract cancer but was terminated early due to lack of survival benefit and increased liver toxicity with NUC-1031.

Clinical Updates news Oncology

Maintaining Quality of Life While Extending Survival: HRQoL Outcomes from KEYNOTE-966 in Advanced Biliary Tract Cancer

By MedXY 09/20/2025

The KEYNOTE-966 trial demonstrates that adding pembrolizumab to gemcitabine and cisplatin improves overall survival in advanced biliary tract cancer patients without compromising health-related quality of life.

Clinical Updates news Oncology

Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma

By MedXY 09/20/2025

The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.

Clinical Updates news Oncology

Innovative DEP-SN38 Nanoparticle Delivery Shows Promise in Advanced Solid Tumors: Safety and Preliminary Efficacy Unveiled

By MedXY 09/20/2025

This phase I study demonstrates that DEP-SN38, a dendrimer-nanoparticle conjugate of SN38, is well tolerated with minimal gastrointestinal toxicity and shows encouraging antitumor activity in heavily pretreated advanced solid tumors.

Clinical Updates news Oncology Specialties

Methylcobalamin Significantly Reduces Severe Hand-Foot Syndrome in HER2 Negative Early Breast Cancer Patients Receiving Capecitabine: Results from a Phase 3 Randomised Trial

By MedXY 09/20/2025

Oral methylcobalamin notably decreased the incidence of grade ≥2 hand-foot syndrome in patients with HER2 negative early breast cancer undergoing adjuvant capecitabine treatment, without added safety concerns, improving treatment adherence potential.

Clinical Updates news Oncology

Efficacy of Liposomal Irinotecan Plus 5-FU/LV in Previously Treated Biliary Tract Cancer: Insights from Pooled NIFTY and NALIRICC Trials

By MedXY 09/20/2025

A pooled analysis of NIFTY and NALIRICC trials demonstrates that liposomal irinotecan combined with 5-FU/leucovorin significantly improves progression-free survival and response rates in previously treated biliary tract cancer, with notable ethnic variations in toxicity profiles.

Clinical Updates news Oncology

Total Tumor Volume: A Superior Predictor of Survival and Chemotherapy Response in Colorectal Cancer Liver Metastases

By MedXY 09/20/2025

This study reveals that total tumor volume (TTV) more accurately predicts overall survival and response to induction chemotherapy than RECIST1.1 in colorectal cancer liver metastases, offering a promising tool for personalized treatment decisions.

Clinical Updates Oncology

Adjuvant Aspirin in PIK3CA-Mutated Colon Cancer: Insights from the SAKK 41/13 Randomized Trial

By MedXY 09/19/2025

The SAKK 41/13 trial provides the first prospective randomized evidence that adjuvant aspirin may improve disease-free survival in patients with resected PIK3CA-mutated stage II and III colon cancer, suggesting its potential as a safe, cost-effective adjuvant strategy.

Clinical Updates news Oncology Specialties

Low-Dose Aspirin’s Impact on PI3K-Altered Localized Colorectal Cancer: New Evidence from a Randomized Controlled Trial

By MedXY 09/19/2025

This randomized trial confirms that daily low-dose aspirin significantly reduces colorectal cancer recurrence in patients with PI3K pathway mutations, highlighting a targeted adjunctive therapy option.

Clinical Updates news Oncology

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY 09/19/2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.

Oncology Urology

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223

By MedXY 09/19/2025

The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metastases, with manageable toxicity and importance of bone-protecting agents.